The Psychiatric Clinics of North America 2003: Vol 26 Index

31 Pages·2003·5.3 MB·English

PSYCHIATRIC
CLINICS OF
NORTH AMERICA
Psychiatr Clin N Am
26 (2003) 1017-1047
Cumulative Index 2003
Volume 26
March SCHIZOPHRENIA: CONTEMPORARY CLINICAL PERSPECTIVES.
pages 1-302
June DRUG THERAPY: PREDICTORS OF RESPONSE, pages 303-528
September WOMEN’S MENTAL HEALTH, pages 529-810
December EVIDENCE-BASED PRACTICES IN MENTAL HEALTH CARE,
pages 811-1047
Vote: Page numbers of article titles are in boldface type.
A endocrine studies, 326-328
Acamprosate, response prediction for, in event-related potentials and.
alcoholism, 390 328-329
imaging studies, 330-336
Addiction treatment services, for substance
neuroendocrine studies, 324-328
use disorders, 1002
neurotransmitters and metabolite
\ddictive disorders, simple phobia and, 639 levels and, 324-325
Addison's disease, psychiatric symptoms in, structural imaging, 330-333
687 Age, as response predictor, to
Administrators, concerns about antidepressants, 357
evidence-based practice, continuous A ge discrimination. women and, 753
training needs and limited training
\ geression. See also Violence
capacities, 929-930
of psychotic patient,
displacement of services of
nonpharmacologic management
established provider
of, 239-242
groups, 929
behavioral. 240-241
investment cost for cost-effective
restraint, 241-244
implementation, 928-929
seclusion, 241-244
Adolescents, automated self-report and, 840 treatment setting in, 239-230
Affective disorders, in children and pharmacologic management of,
adolescents, family functioning and 242-251
interaction styles and, as response Agoraphobia, in panic disorder, 629-630.
predictor, 440-44] 633-634
parental, depression in children and, social anxiety disorder and, 644-645
441
Alcoholism, anxiety in, 389
\ffective illness, response prediction studies, biologic markers for, 3 82-385
calculation of power a priori, 338 cognitive functions in, 386
reporting practical statistics, cravings and urges in. 386
338 cue reactivity in, biologic markes of,
importance in, of homogeneous 384-385
groups, 337 depression in, 388-389
of well-controlled studies, dopamine system in, 382-38 .4
337 dopamine D2 allele in, 383
utilization of all versus specified electroencephalogram in, 384
data, 337-338 expressed emotions of spouse and
response predictors in, family, outcome prediction and.
electroencephalograms, 329-330 388
0193-953X 03 $ - see front matter © 2003 Elsevier Inc. All rights reserved
doi: 10.1016 S0193-953X(03)00099-6
1018 Cumulative Index | Psychiatr Clin N Am 26 (2003) 1017-1047
Alcoholism (continued ) in combination with neuroleptics, for
genetic and environmental causes of, psychotic depression, positive
385 response to, 350
neurotransmitters, neuromodulators, in complex posttraumatic stress
postsynaptic processes and, 383 disorder, 772
opioid deficiency hypothesis for, 383 in generalized anxiety disorder,
opioids and, endogenous, 383 gender differences in, 627-628
personality factors in, 387-388 in geriatric depression, 973-975
pharmacotherapy for, response in menopause, for depression,
predictors in, 389-390 571-572
psychiatric comorbidity in, outcome
and, 388-389
psychological predictors of, 386-390
rapid eyemovement sleep and, 384
self-efficacy, as positive response spontaneous abortion, 55]
predictor, 388 teratogenesis, 551-553
serotonin and, 383 response predictors for, 345-352.
sleep disturbances and, 384 See also Response prediction.
stress and, 386-387 response to, age and gender and,
typology of, 385 589-590
Alcohol use/abuse, comorbid, with bipolar in anxiety disorders, in children
disorder, 600 and adolescents, 446
with panic disorder in women, 633 exogenous estrogen and, in
geriatric, treatment of, 981 postmenopausal women, 590
in geriatric mental health care, 981 gender differences in,
in geriatric population, 581-594, 587-590
pharmacologic and psychosocial in schizophrenia, for negative
treatments for, 981 symptoms, 944
pharmacotherapies for, 996-998 selection principles and, 467-468
switching, to bupropion, 468
Alzheimer’s disease, APO E genotype in, as to mirtazapine, 469
response predictor, 314 to monoamine oxidase inhbitors,
American Psychological Association, 469
clinical psychology division, from selective serontonin reptake
evidence-based practice and, for inhibitors to TCAs, 468
substance use disorders, 994-995 within selective serontonin
criteria for established efficacious reuptake inhbitor class, 468
interventions, in childhood, to velaxafine, 468-469
955-956
Antipsychotic medications, extrapyramidal
Amisulpride, in acute schizophrenia, versus effects of, 941
conventional antipsychotics, 147 first generation, efficacy of. 940-941
versus haloperidol, 147 introduction of, 868-869
versus placebo, 143-144 in schizophrenia, for cognitive
in schizophrenia, for maintenance impairments, 947
treatment, 150 for negative symptoms, 944
for aegative symptoms, 152 for positive symptoms and
Androgens, premenstrual dysphoric relapse, 940-942
disorder and, 532-533 second generation, tolerability and
safety of, 941, 942
Anger, coronary events and, 698
traditional, response to, 942
Antabuse. See Disulfiram ( Antabuse )
Antipsychotics. See also Atypical
Antenatal depression. See Depression, antipsychotics
during pregnancy history of, 191-192
in schizophrenia, acute phase, 217
Anticonvulsants, teratogenic effects of, 606
comorbid with substance abuse,
Antidepressants, in atypical depression, 122
positive response in, 350 late-onset, 106-108
in bipolar disorder, controversies time to remission with, 221
regarding, 507 time to response with, 221
Cumulative Index | Psychiatr Clin N Am 26 (2003) 1017-1047 1019
typical, hyperprolactinemia with, Assertive community training (ACT), for
*
603-604 patients with schizophrenia, 206-207
weight gain, diabetes, dyslipidemia Assertive community treatment, Program
triad with, 165-175 of Assertive Community Treatment,
Antisocial personality disorder, as outcome for schizophrenia, positive symptom
predictor, in cocaine dependence, 395 reduction and relapse, 943
Anxiety, in alcoholism, 389 Association studies, in schizophrenia. 50-51
automated self-report in, 939 catechol-O-methyltransferase
cardiac disease and, 701 and, 51-52
chemotherapy-related, in women with classic markers in, 5]
breast cancer, 717-718 genes in neurodevelopmental
and outcome, of opioid detoxification, process and, 52
396 interprestation of, 52
premenstrual, 605 serotoninergic neurotransmission
in premenstrual syndrome, 535 and, 51
sudden cardiac death and, 701 Attachment, adjustment to trauma and, 767
Anxiety disorder(s), adverse consequences Attention, in schizophrenia, 29
of, 623 sustained, in schizophrenia, 33
comorbidity in, in children and Atypical antidepressants, adverse effects
adolescents, response prediction of, metabolic, 373-374
in, 445-446 cost effectiveness of. in schizophrenia,
comorbid with bipolar disorder, 374-375
600-601 limitations of, 373
DSM-IV classification of, 621 Atypical antipsychotics. See also
generalized anxiety disorder, 624-628 Antipsychotics
genralized anxiety disorder, 412-416 in acute psychotic episodes,
in geriatric mental health care, limitation of, 371
982-983 adverse effects of, 371
lifetime prevalence rate for, 621-622 in bipolar disorder, 9
major depressive disorder risk in, comparison with haloperidol, in
gender and, 622-623 schizophrenia, acute psychotic, 370
obsessive-compulsive disorder, in schizophrenia, 9
421-429 acute phase, 216 217
obsessive-compulsive disorder, adverse effects of, dyslipidemias.
646-652 170-173
in older persons, treatment of, 982-983 glucose metabolism
panic disorder, 629-639 abnormalities,
in women, 632-635 169-170
posttraumatic stress disorder, 418-421, hyperprolactinemia,
652-657 178-181
response predictors in, 411-433 Q-T segment prolongation,
simple phobia, 639-640 175-178
social anxiety disorder, 416-418, sexual, 181-184
640-645 weight gain, 165—169
in women, 621-671, 786 for cognitive deficits, 34-36
with cardiac disease, 700-702 late-onset, 108-111
factors in, 623-624 mechanism of action of, on
prevalence of, U.S. and cognitive deficits, 35-36
worldwide, 622 in substance abuse-schizophrenia
Anxiely symptoms, in women, cardiac comorbidity, 122
rehabilitation and, 697 versus typical antipsychotics, cost
effectiveness of, 374-375
Anxiolytics, for premenstrual dysphoric
reduction of rehospitalization,
disorder, 539
374-375
Arachadonic acid (AA). See Essential versus typical neuroleptics, 368-369
polyunsaturated fatty acids (EPUFAs
Auditory event-related brain potentials, as
Aripiprazole, comparison with risperidone response predictors, in antidepressant
or olanzapine, in schizophrenia, 370 therapy, 359
1020 Cumulative Index | Psychiatr Clin N Am 26 (2003) 1017-1047
Auditory evoked potentials, response to neuropathology in, 6—7
serotonergic antagonists and, 358 overlapping issues in, 9-10
pathophysiology in, 10
Augmentation studies, for major depressive:
treatment response in, 8—9
disorder, 464-465
depression in, 495-496
Automated clinical treatment (ACT) gender differences in, 595-620
systems, 844 age of onset and, 595
Automated self-report (ASR), adult patient comorbidity and, 599-601
and, acceptance of, 841-842 depressive episodes and, 596
diagnostic, child-structured, 840-841 mixed mania and, 598-599
integrated, 836-837 psychiatric comorbidity in,
screening interviews, 837-838 600-601
self-disclosure on, 842 psychosocial outcome and, 601
severity rating systems and, 838-842 rapid cycling and, 596-598
for obsessive-compulsive seasonal changes and, 595-596
disorder, 839-840 suicidality and, 601-602
treatment and, 603-604
Avoidant personality disorder, social parental, mood disorder in children
anxiety disorder and, 643 and, 441
psychological interventions in,
B cognitive behavioral therapy. 513
Behavioral couples therapy, 999 family therapy, 514
goals of, 512-513
Benzodiazepines, for aggressive patient interpersonal and social rhythms
with schizophrenia, 250 therapy, 513
in generalized anxiety disorder, in psychotherapy and STEP-BD, 514
women, 628 reproductive cycle and, 604-610
in panic disorder, 631, 637 lactation in, 608-609
in social anxiety disorder, 644 menopause in, 609-610
Beta-blockers, for aggressive patient with menstrual cycle in, 604-605
schizophrenia, 250 postpartum in, 607-608
pregnancy in, 605-607
Bipolar disorder (BPD), in children and social anxiety disorder and, 642
adolescents, consequences of, 438 STEP-BD approach in, 495-518
diagnostic difficulty in, 437-438 acute phase therapy, 499-507
prognosis in, 438 antidepressant therapy in,
psychotic features in, response to controversies in, 507
treatment and, 444 break-through depressive
relapse in, 438 episodes. 507-510
response predictors in, age, 439 bupropion in, 508, 510
demographic, 438-440 carbamazepine in, 506
family environment, citolapram in, 509-510
440 442 divalproex sodium in, 503-505
gender and, 438-439 expert practice guidelines in,
psychosocial, 440-442 496-499
referral source, 439 gabapentin in. 506
subtypes of, as response lamotrigine in, 501-503
predictors, 444-445 lithium in, 501, 507—S08
symptom presentation in, long-term therapy in, with
443-444 antidepressants, 511-512
comorbidity in, in children and moclobemide in, 511
adolescents, response to lithium monoamine oxidase inhibitors
in, 447 in, 510-511
comparison with schizophrenia. mood stabilizer monotherapy
2-10, 14 in, 496, 500-507
causes of, 6 olanzapine in, 505-506
characterization in, 3-4 paroxetine in, 508-509
cognitive performance in, 3 psychological interventions in,
demographics in, 4-5 512-514
epidemiology in, 5-6
Cumulative Index | Psychiatr Clin N Am 26 (2003) 1017-1047
selective serotonin reuptake Bupropion (BUP), in break-through
inhibitors in, 508-510 depression, 510
topiramate in, 506 response to, in typical versus atypical
tranyleypromine in, 510-511 depression, 355
venlaxafine in, 510 with selective serotonin reuptake
in women, 287 inhibitors, in treatment-resistant
evaluation of, 610 depression, 467
with obsessive-compulsive
Burden, definitions of, 782
disorder, 650
of mental illness, in women, 781-782
risk factors for, 787
treatment implications for, 787 Buspirone (BUS), augmentation, in
treatment-resistant depression, 466
Bipolar II disorder, comparison with
bipolar I disorder, 602 c
gender differences in, 602-603
rapid cycling and, 596-597 Calcium supplementation, for premenstrual
pharmacotherapy for, 602-603 dysphoric disorder, 537
rapid cycling in, 596-597
Candidate genes, in pharmacogenomics,
Bone marrow transplantation, in women 306-307
with breast cancer, 719 studies of clozapine response,
309--310
Boundaries, of schizophrenia, 1-24
in pharmacogenomic studies of
Brain, neuropathology of, in schizophrenia clozapine response, 309-310
and bipolar disorder, 6-8 and polymorphisms, in
pharmacogenomics, 306-307
Breast cancer, psychiatric aspects of,
713-724 Carbamazepine, in bipolar disorder, 506
in women, adjuvant chemotherapy for, response to, in mixed mania, 599
717-718 serum concentration, in nursing
advanced disease, 719-720 infants, 609
biopsychosocial impact of, Cardiovascular disease, in women, cardiac
715-716 rehabilitation and, 696
bone marrow transplantation for, cardiac transplantation and,
719
695-696
early detection and decision coronary revascularization and,
making and, 714-715 694-695
family and, 721 demographics of, 693-694
hormonal therapy for, 718-719 depression and anxiety and,
incidence of, 713 700-701
lumpectomy and radiation education and employment and,
therapy, 717 699-700
management of distress in, 716 mental health issues in, 693-712
mastectomy for, 716-717 myocardial infarction mortality
medical factors in, 716 and, 694
metastatic, treatment of, psychosocial factors in, 698-702
719-720 social support and, 699
psychiatric consultation in, type A personality and, 698
715-716, 720
psychosocial intervention in, 720 Care pathway, quality care and, 222223
treatment of, physiologic or Catechol-O-methyltransferase, in
psychosocial disability schizophrenia, gene coding for, 51-52,
from, 721-722 115
Brief interventions, for substance use Catechol O-methyltransferase (COMT),
disorders, 999 dopamine metabolism and, 312
genetic forms of, 306, 312
Brief strategic family therapy (BSFT), for
substance use disorders, 1000 Center for Mental Health Services (CMHS),
Buprenorphine, in opioid use disorders, 998 administration of block grant, 915
Children’s Services Grant Program of.
Bupropion, fetal exposure to, 553 evidence-based practice in, 961
1022 Cumulative Index | Psychiatr Clin N Am 26 (2003) 1017-1047
(CMHS) (continued) polygenetic predisposition to, 735
collaboration with NIMH in planning, psychological factors in, 735
fielding, evaluating sociocultural factors in, 735
demonstration programs, 912 linkage of, epidemiologic, 726-727
Character dimensions, as response pathophysiologic, 727
predictor, to antidepressants, 361 response to treatment and,
727-728
Childhood abuse, anxiety disorders and, in women, 725-740
623-624 bidirectional relationship in, 726
Childhood sexual abuse, effects of, 761 comorbidity, linkage,
posttraumatic stress disorder and, 655 pharmacologic response in,
premenstrual syndrome/premenstrual 725-728
dysphoric disorder and, 535-536 depressive disorders and,
prevalence of, 760 728-731
fibromyalgia, 733-734
Childhood trauma, disturbances following,
760-761 irritable bowel syndrome.
732-733
Children, automated self-report and, migraine headaches, 731-732
840-841
evidence-based practice and, 955-969 Cigarette smoking, in schizophrenia, 126
American Psychological Citalopram (CIT), in break-through
Association criteria for depression, 509-510
established efficacious in STAR*D protocol, continuation
interventions, 955-956 with, 482-483
community-based service as first-step agent, 479
models, 958-960
Clinic/community intervention
disorders and treatments for,
956-957 development model, evidence-based
practice and, 964-965
dissemination of, questions in,
965-966 Clomipramine, for premenstrual dysphoric
family education and support, disorder, 539
958-959
Clonazepam, comparison with cognitive
future and, 962-966
initiatives in, 960-962 behavioral therapy, for outcome, in
social phobia, 418
intensive community-based
interventions, 958 Clonidine, for complex posttraumatic
knowledge base and, 956-960 stress disorder, 773
MacArthur Foundation Child
Mental Health Initiative Clozapine, advantages of, 367-368
and, 962 for aggressive patient with
merger of research and practice schizophrenia, 247-248
and, 963 comparison with haloperidol, for cost
multi-systemic therapy, 958-959 effectiveness, 375
psychopharmacology and, versus haloperidol, in relapse
957-958 reduction, in schizophrenia, 372
reduction of gap between response of, to dopamine genes,
research and practice, 963 309-310
residential treatment and group in schizophrenia, for cognitive deficits,
homes, 958 34-36
safety in research and, 963-964 for depression, 945
treatment foster care, 958-959 history of, 367-368
late-onset, 108-109
Cholinesterase inhibitors, in dementia, in refractory to treatment, 156, 158.
geriatric population, 980 192
Chromosomal abnormalities, in suicide reduction and, 124
schizophrenia, 52-53 for violence and suicidality, 946
and smoking cessation, 126
Chronic episodic disorder(s) (CEDs),
triglyceride level increase with, 171
commonalities of, 725
gender differences in, biologic factors Cocaine addiction, pharmacologic
in, 734-735 research in, 999
Cumulative Index | Psychiatr Clin N Am 26 (2003) 1017-1047
Cocaine dependence, concurrent alcoholism impaired, 31-32
and, treatment response and, 394 learning and memory and, 30-31
outcome predictors in, baseline versus rehabilitation outcome and,
proximal, 392-393 33-34
5
craving, 394-395 specific deficits in, 27—31
drug and alcohol comorbidity, 394 working memory and, 27-28
gender, 393 Cognitive remediation, for schizophrenia,
psychopathology, 393-394 203-204
psychosocial treatment
interaction with, 392 Combination therapy, in treatment-resistant
severity of dependence, 391-392 depression, 466-467
Cognitive behavioral therapy, with Command hallucinations, violence and, 235
pharmacotherapy, in schizophrenia, Comorbidity, in schizophrenia, 115-139
coping strategy enhancement in, depressive disorders. 116-118
197-198 detection and management of,
for negative symptoms, 115-139
198-199 medical, 125-130
for residual symptoms, 197 obsessive-compulsive symptoms.
in schizophrenia, for obsessive- 118-120
compulsive symptoms, |20 psychiatric, 116-124
substance abuse. 120-123
Cognitive behavioral therapy (CBT), in
suicide, 123-124
bipolar disorder, 513
for children, for internalizing disorder, Complex posttraumatic stress disorder,
61 nonpharmacologic treatment of,
for complex posttraumatic stress 770-771
"79 777
disorder, 772 pharmacotherapy for, 772-773
discontinuation of antidepressant treatment of, staged approach to,
therapy and, 556-557 770-771
for posttraumatic stress disorder, 769 Composite International Diagnostic
for premenstrual dysphoric disorder, Interview (CIDI), 836
538
Consent, and pharmacogenomics, 315
response to, in children and
adolescents, with major Consent to treatment, capacity for, in
depression and comorbid anxiety, aggressive patient with schizophrenia.
446 251-252
for schizophrenia, 944-945 Consumers, concerns about evidence-based
positive symptom reduction and practice, 922-923
relapse, 943-944 consumers versus researchers on
for substance use disorders, 1000 outcomes, 925-926
Cognitive deficits, in schizophrenia, in funding competition, will only
antipsychotic therapies for, 34-36 evidence-based practice
functional consequences of, survive, 921, 924
31-34 researchers and professions will
diminish consumer power,
Cognitive function, in alcoholism, 925
treatment outcome and, 386 use of treatment evidence-based
characterization of, 25 practice algorithms may
chemotherapy and, in women with prevent individualized
breast cancer, 718 treatment, 924-925
in menopause, 572-573 and families, in implementation of
in schizophrenia, 244 evidence-based practice. 867-881
attention and information
Contingency management (CM), for
processing and, 29
contemporary understanding, substance use disorders, 1000
26-27 Coping strategies. adjustment to trauma
correlation with functional and, 767
outcome, 32-33 in substance dependencies, 387
executive function and, 28-29 women, for role conflict or overload,
historical perspective, 26 749-750
1024 Cumulative Index | Psychiatr Clin N Am 26 (2003) 1017-1047
Corticosteroids, dexamethasone in adolescents, cognitive distortions in,
suppression test and, 325-326 pharmacologic treatment of, 444
in alcoholism, response prediction
Corticotropin-releasing factor (CRF), in
and, 388-389, 394
irritable bowel syndrome, 733
automated self-report in, for major
Cortisol, treatment response and, 325 active, 839
for screening, 839
Costs, of mental illness, direct and in bipolar disorder, gender differences
indirect, 782 in, 596
Counseling, for substance use disorders, break-through, in bipolar disorder.
1000 507-510
bupropion for, 510
Craving, as outcome predictor, in cocaine selective serontonin reptake
dependence, 394-395 inhibitors for, 508-510
Cravings and urges, in alcoholism, relapse venlafaxine for, 510
prediction and, 386 cardiac disease and, 701-702
chemotherapy-related, in women with
Cushing's syndrome, psychiatric breast cancer, 718
symptoms in, 686 in children and adolescents, 437
diagnostic criteria for, 443
D severity of, as outcome predictor,
444
Danazol, for premenstrual syndrome
in cocaine dependence, relapse and.
premenstrual dysphoric disorder,
393-394
539-540
response to treatment and, 394
Dehydroepiandrosterone (DHEA), and comorbid, in generalized anxiety
response to ECT, 326 disorder, 625
in women, 783
Dehydroepiandrosterone sulfate
comorbidity in, 586, 726-727
(DHEA-S), ECT response
comoribity in, 354
prediction and, 360
epidemiology of, 581-582
as response predictor, to ECT,
gender differences in, 581, 581-594
359-360
antidepressant treatment and,
Deinstitutionalization, antipsychotic pharmacokinetics of,
medications and, introduction of, 586-590
868-869 response to treatment.
coping with basic living abd, 869-870 $87-590
evidence-based practice Project and, in clinical features of
870-871 comorbidities and, 586
core interventions for outpatient etiology of, 582-585
setting, 870-871 life event stress and, 583-584
family and, as case manager, 870 neurobiologic factors in, 584-585
through National Alliance for the in prevalence, 582-585
Mentally Ill, 871-872 psychosocial factors in, 584
mental health care system and, 868 symptoms, comorbidities, and
peer support interventions and, 871, course of illness, 585-586
875 in geriatric mental health care,
Delusions, violence and, 235-236 973-977
antidepressants for, 973-975
Dementia, in geriatric mental health care, psychosocial treatments for,
977-980 975-976
pharmacologic treatments for, impact of, 582
978-980 lifetime prevalence of, 581—S82
psychosocial and environmental major, subtypes of, 354
modifications in, 978-980 marijuana use and, 394
Dementia praecox, 104-105 melancholic, treatment effectivness in,
schizophrenia and, 1-4 355
menopausal, 570
Depression. See also Major depressive characteristics of, 571
disorder (MDD)
Cumulative Index | Psychiatr Clin N Am 26 (2003) 1017-1047 1025
treatment strategies for, 571-572 Dexamethasone-corticotropin-releasing
migraine headaches and, in women, hormone test, in depression, response
731-732 prediction and, 359
postpartum, 785, 792
prediction of, with tryptophan Dexamethasone suppression test (DST), in
depletion, 360 depression, as response predictor, 359
during pregnancy, 547-562 as response predictor, 359
antidepressant use and, 550-55 in adults, 447-448
medical disorder-related. 549 in children and adolescents, 447
nonpharmacologic treatment of, for treatment response prediction,
550 325-326
relapse and, 548-549
Diabetes, atypical antipsychotic-related, 170
risk factors for, 548
type 2, antipsychotic
treatment of, 555-558
medication-related, in
nonpharmacologic,
schizophrenia, 128—130
556-558
pharmacologic, 557-558 Diabetes mellitus, 687
risks associated with, 556 in women, psychiatric disorders with,
untreated, risks of, 549-550 688
response prediction in, duration of sexual dysfunction with, 688
treatment and, 356 ; ; :
neuroanatomic predictors, 362 Diagnostic Interview Schedule (DIS), 836
response predictors in, biochemical, automated self-report version, 836-83
ne : : :
359- 361 ieee Diagnostic Interview Schedule Screening
clinical, 354-357 a Interview (DISSI), 837
demographic, 357-358
endocrinologic, 359-361 Diet, for premenstrual dysphoric disorder,
‘peers c1¢ £29
physiologic, 358-335 9 536-537
risk factors for, in ; Dissociation, posttraumatic stress disorder
obsessive-compulsive and. 764-765
disorder, 650
in women, 784-785 Disulfiram (Antabuse), for alcohol use
in schizophrenia, medications for, 945 disorders, 996-997
severity of, as predictor of response, response prediction for, 390
355-356 in substance abuse-schizophrenia
as syndrome, 354 comorbidity, 123
in women, with breast cancer, 718, 720
Divalproex, for bipolar disorder with
with generalized anxiety disorder,
migraine headaches, 599
626-627
response to, in bipolar disorder,
interventions and, 785
rapid-cycling, 597
risk factors for, 784-785
Divalproex sodium, in bipolar disorder.
Depressive disorders, in schizophrenia, Re
116-117 503-305
detection of, 117-118 Docosahexaenoic acid (DHA). See Essential
management of, 118 polyunsaturated fatty acids (EPUFAs
prognostic significance of, 117
in women, 783 Dopamine receptors, clozapine response
versus men, 728 and, 309-310
perimenopause and menopause Dyslipidemias, atypical
and, 730-731 : antipsychotic-“ related, 170-17732
postpartum, 729-730
premenstrual dysphoric disorder Dy sthymia, social anxiety disorder and, 642
and, 729 in women, with hypopituitarism, 684
Depressive symptoms, in women, cardiac
rehabilitation and, 697 E
with diabetes mellitus, 688
Eating disorders, in women, with diabetes
with hypothyrodism, 685
mellitus, 688
radiation therapy for breast
cancer and, 717 EBM. See Evidence-based medicine (EBM
1026 Cumulative Index | Psychiatr Clin N Am 26 (2003) 1017-1047
Education, of psychiatrists, clinical Estrogen, in chronic episodic disorders, 727
computing in, 844-845 premenstrual dysphoric disorder and,
PDAs in, 844-845
in sexual function, 674-676
Electroconvulsive therapy (ECT),
postseizure fractal dimension in, in withdrawal of, panic disorder and, 636
response prediction, 358 Estrogen replacement therapy (ERT),
during pregnancy, 558 antidepressant response and,
Electroencephalogram (EEG), beta exogenous estrogen and, 590
activity in, in alcoholism, 384 in menopause, for cognition
in major depressive disorder, ECT enhancement, 572-573
response and, 329-330 for depression, 572
multichannel, response to depression for hot flushes, 567-568
and, 362 with sleep disturbance, 570
as response predictor, in children and for quality of life enhancement,
adolescents, 449 574
Electronic medical record (EMR), in Event-related brain potentials (ERBPs),
psychiatry, current state of, 834-835 response predictor to antidepressants,
potential for, 834 359
Endocrine disorders, psychiatric aspects Event-related potentials (ERPs). See also
of, 683-691 Loudness dependence of
in women, diabetes mellitus, 687-689 auditory-evoked potential (LDAEP
glucocorticoid, 686-687 response to pharmacotherapy and, in
hypothalamic—pituitary, 683-685 obsessive-compulsive disorder,
hypothalamic-—pituitary—adrenal 427
axis, 686
hypothalamic—pituitary—thyroid Evidence, transfer into clinical practice,
axis, 685-686 213-214
parathyroid, 689
Evidence-based medicine (EBM), finding
psychiatric aspects of, 683-691
and evaluating evidence in,
Enteric nervous system (ENS), 733 821-831, 826-827
Environment, genetic susceptibility and, clinical vignette of multi-problem
in schizophrenia, 5 assessment and multi-modal
treatment, 822-834
Essential polyunsaturated fatty acids
literature search in, 827
(EPUFAs), antipsychotic medication
question formulation in, 824
and, 86
for interventions, 825-826
in schizophrenia, in augmentation of
for outcomes, 826
antipsychotic therapy, 97
patient’s population and,
brain phospholipids in,
825
functional organization of,
finding the evidence and evaluating
87-89
evidence in, computerized
sources and metabolic
searches, 827
pathways of, 88, 90
consultation of primary sources,
membrane phospholipids in,
829-830
breakdown of, 91-92
evidence-based practices and,
metabolism of, 90-91
827-828
antipsychotic
systematic reviews in, 828-829
treatment effects
use of evidence, 830
on, 92-93
computer-based decision
dysregulation of,
support systems, 830
94-97
mental health care and, clinical
and neurodevelopment, 93
expertise and, 816-817
and signal transduction,
consumer and, 816
93-94
informed shared decision-making
synthesis of, 90-91
and, 816-817
supplementation of, 94-96
policy level and, 817-818
with antioxidants, 96
principles in, 814
Estradiol, in menopause, 564, 566 risk and adjusted risk, 816